מקרה בראומטולוגיה דר ענת שיימן. בת 39 סובלת מכאבים בכפות ידיים וכפות רגליים 6 חודשים טרם קבלתה.

Slides:

Advertisements

Similar presentations

Disease Modifying Anti-Rheumatic Drugs (DMARDs) Immunomodulatory and immunosuppresive Xenobiotic – Gold salts – Azathioprine – Methotrexate Biological.

Advertisements

Hatem H Eleishi, MD Professor of Rheumatology, Cairo University Consultant Rheumatologist, Dr. Soliman Fakeeh Hospital Rheumatoid Arthritis Wednesday,

Drug Therapy for Rheumatoid Arthritis in Adults Prepared for: Agency for Healthcare Research and Quality (AHRQ)

Efficacy of Methotrexate and/or Etanercept for treatment of RA Rheumatoid Arthritis:

Treatment Management of Rheumatoid Arthritis. Findings and In Depth Analysis.

1 Abatacept Brian Daniels, M.D. Senior Vice-President Global Clinical Development Bristol-Myers Squibb.

The Use of Tocilizumab (Actemra®), an Interleukin-6 receptor antagonist, for the treatment of rheumatoid arthritis in Methotrexate Refractory patients.

Table 1. Comparison between the provisional diagnosis based on the proforma versus final diagnosis Early arthritis Rheumatoid arthritis 3 6 Psoriatic.

What is the definition of remission in RA? American Rheumatism Association (ARA)¹ Five or more of the following criteria must be fulfilled for at least.

Remission in Established RA Patients

Measuring Signs and Symptoms in Rheumatoid Arthritis David R. Karp, MD, PhD Chief, Rheumatic Diseases UT Southwestern Medical Center David R. Karp, MD,

Hot Topics in Rheumatology Prof. MG Molloy. Overview Rheumatoid Arthritis Psoriatic Arthritis Vasculitides: SLE Osteoarthritis Osteoporosis.

Treatment of Rheumatoid Arthritis Then and Now

Rituximab for the Treatment of Rheumatoid Arthritis

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis.

Abatacept (ORENCIA) for Rheumatoid Arthritis Biological License Application Arthritis Advisory Committee September 6, 2005.

Achieving remission in early RA Dubai, United Arab Emirates 19. January 2009 Professor Joachim Kalden Friedrich-Alexander University Erlangen-Nuremberg.

Arthritis Advisory Committee August 16, 2001

EFFICACY OF SPA THERAPY IN RHEUMATOID ARTHRITIS-A RANDOMISED CONTROLLED CLINICAL STUDY Mine Karagülle Department of Medical Ecology and Hydroclimatology.

( Slow Acting Anti-inflammatory Drugs ). OBJECTIVES At the end of the lecture the students should Define DMARDs Describe the classification of this group.

Infectious arthritis Bacterial Viral Other Postinfectious (reactive) arthritis Rheumatic fever Reactive arthritis Enteric infection Other seronegative.

Outcome Measures in PsA Philip Mease MD Seattle, WA.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2013 update Smolen.

Date of download: 6/24/2016 From: Effectiveness of Manual Physical Therapy and Exercise in Osteoarthritis of the Knee: A Randomized, Controlled Trial Ann.

Tumor necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis The Annals of the.

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis R1 신가영 / Modulator Prof. 이연아 N Engl J Med 2015; 373: Philip J.

A NEW LOOK AT RA Interactive Hot Topics Series

A NEW LOOK AT RA Interactive Hot Topics Series

Volume 18, Issue 2, Pages (March 2015)

A NEW LOOK AT RA Interactive Hot Topics Series

Rheumatoid Arthritis Management: Turning Treatment Failures Into Successes Supported by an educational grant from Lilly USA, LLC.

A NEW LOOK AT RA Interactive Hot Topics Series

From: Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled TreatmentA Randomized Trial Ann Intern Med.

From: Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic AgentsA Cost-Effectiveness.

The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of.

Rheumatoid arthritis The Lancet

Chief investigator- Dr. Kripasindhu Gantait, Associate Professor

Ann Intern Med. 1999;130(6): doi: / Figure Legend:

From: Systematic Review: Strategies for Using Exercise Therapy To Improve Outcomes in Chronic Low Back Pain Ann Intern Med. 2005;142(9): doi: /

From: Treatment of Refractory Whipple Disease with Interferon-γ

My Treatment Approach to Rheumatoid Arthritis

Recommendations for the treatment of established RA (disease duration 6 month or longer). Biologic, biological originator DMARD or boDMARD; DMARD, disease-modifying.

Prediction of Response to Targeted Treatment in Rheumatoid Arthritis

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis Dao X. Nguyen, BSc, Alice Cotton, RN, BSc, Laura Attipoe, MBBS, Coziana.

Introduction/Background

My Treatment Approach to Rheumatoid Arthritis

BeSt Study: Patient Characteristics Total Population Female 67% Male % Age (years) Duration of symptoms (weeks) 23 Time diagnosis.

What’s new in my specialty- Rheumatoid Arthritis

Association between anti-CCP antibody status and response to remission, LDA and mACR by anti-CCP status and TNFi initiators (multivariable models). Association.

Viewpoints of Practicing Rheumatologists: Case Discussions in RA

Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI

Changes in clinical disease activity over 24 months on a continuous scale in SWEFOT trial participants randomised to triple therapy or anti-TNF with available.

Rheumatoid Arthiritis

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.

Prescription rates of (A) NSAIDs, glucocorticoids and analgaesics, (B) TNF inhibitors and synthetic DMARDs and (C) combination therapy of NSAIDs with TNF.

Low-dose glucocorticoid chronotherapy in rheumatoid arthritis (RA) include the night-time-release prednisone, a timing drug release formulation with administration.

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Patient-reported adherence towards different IMID treatments in RA (A), PsA (B) or AS (C). Patient-reported adherence towards different IMID treatments.

Clinical response in patients with early and established RA at month 24. *p

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.

Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate.

Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.

Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.

Multivariable model of adjusted

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Suggested therapeutic management according to subtypes and severity of rheumatic immune-related adverse events (irAE). *Add-on therapy with DMARDs (disease-modifying.

Presentation transcript:

מקרה בראומטולוגיה דר ענת שיימן

בת 39 סובלת מכאבים בכפות ידיים וכפות רגליים 6 חודשים טרם קבלתה.

שאלות נוספות ?

בבדיקה

אבחנה מבדלת ?

Parvovirus B19 Rubella Hepatitis B,C PMR Adult Stills disease SLE Palindromic rheumatism Remitting seromegative symetrical synovitis with PE (RS3PE)

בדיקות נוספות ?

Anti CCP positive RF positive ESR 70 CRP 1.5 (0-0.5)

אבחנה וגורמים פרוגנוסטיים ?

פרוגנוזה תפקוד נזק רנטגני APR סרולוגיה Shared epitope on the HLA-DR

טיפול ? MTX HCQ SSZ Combination MTX+HCQ MTX+SSZ+HCQ MTX+SSZ+HCQ+Prednisone Prednisone Anti TNF

אחרי 3 חודשים : נפיחות ב 5 מפרקים, ESR 50, VAS 50 DAS

What is DAS? DAS28 Calculator Enter clinical data: tender joint count (0-28) swollen joint count (0-28) ESR (mm/hr) VAS general health patient (mm) Remission: DAS28 ≤ 2.6 Low Disease activity: 2.6 < DAS28 ≤ 3.2 Moderate Disease Activity: 3.2 < DAS28 ≤ 5.1 High Disease Activity: DAS28 >5.1 DAS28 = Disease Activity Score assessing 28 joints (range, 0 to 9.3)

טיפול ? MTX HCQ SSZ Combination MTX+HCQ MTX+SSZ+HCQ MTX+SSZ+HCQ+Prednisone Prednisone Anti TNF +MTX

SWEFOT In patients with early rheumatoid arthritis in whom methotrexate treatment failed, addition of a tumor necrosis factor antagonist to methotrexate monotherapy is clinically superior to addition of conventional disease- modifying antirheumatic drugs.

IE = immediate methotrexate (MTX) plus etanercept; IT = immediate triple therapy (MTX plus sulfasalazine [SSZ] plus hydroxychloroquine [HCQ]); SE = step-up from MTX to MTX plus etanercept; ST = step-up from MTX to triple disease-modifying antirheumatic drug (DMARD) therapy (MTX plus SSZ plus HCQ)

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial Arthritis & Rheumatism Volume 64, Issue 9, pages , 27 AUG 2012 DOI: /art Volume 64, Issue 9,

TEAR

Initial use of MTX monotherapy with the addition of sulfasalazine plus hydroxychloroquine (or etanercept, if necessary, after 6 months) is a reasonable therapeutic strategy for patients with early RA. Treatment with the combination of MTX plus etanercept resulted in a statistically significant radiographic benefit compared with oral triple therapy.

לתת סטרואידים ?

Date of download: 1/13/2014 Copyright © American College of Physicians. All rights reserved. From: Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis: A Randomized Trial Ann Intern Med. 2012;156(5): doi: / Individual patients' erosion scores. Totals of 112 and 110 patients were analyzed for the MTX and prednisone group and the MTX and placebo group, respectively. Arrows with percentages show the proportion of patients within each treatment strategy with no erosions at 2 y. MTX = methotrexate.

Date of download: 1/13/2014 Copyright © American College of Physicians. All rights reserved. From: Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis: A Randomized Trial Ann Intern Med. 2012;156(5): doi: / Course of disease activity variables during 2 years of treatment, based on pooled results of imputed analyses. * Significant differences between both treatment strategies at 3 mo, 6 mo, 1 y, 18 mo, or 2 y of treatment.

conclusion

החולה טופלה ב MTX+HCQ+SSZ ובהמשך ב MTX+ ETN הגיבה בתחילה אך כעת פנתה בשל כאבים בשוק ימין מאתמול. בבדיקה...

לחולה עדיין כאבי בכפות ידיים ורגליים, DAS 28-3

RTX- chimeric monoclonal AB against CD 20. TCZ- humanized monoclonal Ab against IL-6R. ABT-opposes co- stimulatory molecules which assist with binding of immune cells to T-cells

What is ACR 20, 50, 70? acute phase reactant patient assessment physician assessment pain scale disability/functional questionnaire

בשל חוסר שיפור על ETN+MTX, הוחלף הטיפול ל ADA + MTX

חל שיפור בכאבים, DAS מזה כחודש שיעול. אבחנה מבדלת ?

הטיפול בנוגדי TNF הופסק. השלימה טיפול בשחפת. אילו אפשרויות יש כעת לטיפול ב RA ?

תחת RTX, התיצבה. טופלה כחמש שנים.

סובלת כחודש מכאבים בצואר. אבחנה מבדלת ? בדיקות נוספות ?

Lateral view of the cervical spine done as a cross-table lateral shows a marked increase in the distance between the anterior surface of the dens and the posterior surface of the C1 tubercle (blue arrow) that measured 14 mm (black line), well in excess of the 3 mm maximum in adults. The imaginary line connecting the spinolaminar white lines (white line) shows that the body of C1 (red arrow) is displaced anteriorly relative to the remainder of the spine.

conclusions MTX does work as do combination DMARDs and steroids. Should you try another TNFi? Now what? The non-TNFi biologics Are there differences in efficacy?

Where not to use anti TNF?